Alan Moss1, Stephen J Williams2, Luke F Hourigan3, Gregor Brown4, William Tam5, Rajvinder Singh5, Simon Zanati6, Nicholas G Burgess7, Rebecca Sonson2, Karen Byth8, Michael J Bourke7. 1. Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, Australia Department of Endoscopy, Western Health and The University of Melbourne, Melbourne, Australia. 2. Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, Australia. 3. Department of Gastroenterology, Princess Alexandra Hospital, Brisbane, Australia. 4. Department of Gastroenterology, The Epworth Hospital, Melbourne, Australia Department of Gastroenterology, The Alfred Hospital, Melbourne, Australia. 5. Department of Gastroenterology, Lyell McEwin Hospital, Adelaide, Australia. 6. Department of Endoscopy, Western Health and The University of Melbourne, Melbourne, Australia Department of Gastroenterology, The Alfred Hospital, Melbourne, Australia. 7. Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, Australia Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia. 8. Medical Statistician, Research and Education Network, Westmead Hospital and Sydney University, Sydney, New South Wales, Australia.
Abstract
OBJECTIVE: Wide-field endoscopic mucosal resection (WF-EMR) is an alternative to surgery for treatment of advanced colonic mucosal neoplasia up to 120 mm in size, but has been criticised for its potentially high recurrence rates. We aimed to quantify recurrence at 4 months (early) and 16 months (late) following successful WF-EMR and identify its risk factors and clinical significance. DESIGN: Ongoing multicentre, prospective, intention-to-treat analysis of sessile or laterally spreading colonic lesions ≥20 mm in size referred for WF-EMR to seven academic endoscopy units. Surveillance colonoscopy (SC) was performed 4 months (SC1) and 16 months (SC2) after WF-EMR, with photographic documentation and biopsy of the scar. RESULTS: 1134 consecutive patients were enrolled when 1000 successful EMRs were achieved, of whom 799 have undergone SC1. 670 were normal. Early recurrent/residual adenoma was present in 128 (16.0%, 95% CI 13.6% to 18.7%). One case was unknown. The recurrent/residual adenoma was diminutive in 71.7% of cases. On multivariable analysis, risk factors were lesion size >40 mm, use of argon plasma coagulation and intraprocedural bleeding. Of 670 with normal SC1, 426 have undergone SC2, with late recurrence present in 17 cases (4.0%, 95% CI 2.4% to 6.2%). Overall, recurrent/residual adenoma was successfully treated endoscopically in 135 of 145 cases (93.1%, 95% CI 88.1% to 96.4%). If the initial EMR was deemed successful and did not contain submucosal invasion requiring surgery, 98.1% (95% CI 96.6% to 99.0%) were adenoma-free and had avoided surgery at 16 months following EMR. CONCLUSIONS: Following colonic WF-EMR, early recurrent/residual adenoma occurs in 16%, and is usually unifocal and diminutive. Risk factors were identified. Late recurrence occurs in 4%. Overall, recurrence was managed endoscopically in 93% of cases. Recurrence is not a significant clinical problem following WF-EMR, as with strict colonoscopic surveillance, it can be managed endoscopically with high success rates. TRIAL REGISTRATION NUMBER: NCT01368289. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: Wide-field endoscopic mucosal resection (WF-EMR) is an alternative to surgery for treatment of advanced colonic mucosal neoplasia up to 120 mm in size, but has been criticised for its potentially high recurrence rates. We aimed to quantify recurrence at 4 months (early) and 16 months (late) following successful WF-EMR and identify its risk factors and clinical significance. DESIGN: Ongoing multicentre, prospective, intention-to-treat analysis of sessile or laterally spreading colonic lesions ≥20 mm in size referred for WF-EMR to seven academic endoscopy units. Surveillance colonoscopy (SC) was performed 4 months (SC1) and 16 months (SC2) after WF-EMR, with photographic documentation and biopsy of the scar. RESULTS: 1134 consecutive patients were enrolled when 1000 successful EMRs were achieved, of whom 799 have undergone SC1. 670 were normal. Early recurrent/residual adenoma was present in 128 (16.0%, 95% CI 13.6% to 18.7%). One case was unknown. The recurrent/residual adenoma was diminutive in 71.7% of cases. On multivariable analysis, risk factors were lesion size >40 mm, use of argon plasma coagulation and intraprocedural bleeding. Of 670 with normal SC1, 426 have undergone SC2, with late recurrence present in 17 cases (4.0%, 95% CI 2.4% to 6.2%). Overall, recurrent/residual adenoma was successfully treated endoscopically in 135 of 145 cases (93.1%, 95% CI 88.1% to 96.4%). If the initial EMR was deemed successful and did not contain submucosal invasion requiring surgery, 98.1% (95% CI 96.6% to 99.0%) were adenoma-free and had avoided surgery at 16 months following EMR. CONCLUSIONS: Following colonic WF-EMR, early recurrent/residual adenoma occurs in 16%, and is usually unifocal and diminutive. Risk factors were identified. Late recurrence occurs in 4%. Overall, recurrence was managed endoscopically in 93% of cases. Recurrence is not a significant clinical problem following WF-EMR, as with strict colonoscopic surveillance, it can be managed endoscopically with high success rates. TRIAL REGISTRATION NUMBER: NCT01368289. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: F Bianco; A Arezzo; F Agresta; C Coco; R Faletti; Z Krivocapic; G Rotondano; G A Santoro; N Vettoretto; S De Franciscis; A Belli; G M Romano Journal: Tech Coloproctol Date: 2015-09-24 Impact factor: 3.781
Authors: Neal Mehta; Ashraf Abushahin; Meena Sadaps; Mohammad Alomari; John Vargo; Deepa Patil; Rocio Lopez; Matthew Kalady; Conor P Delaney; Emre Gorgun; James Church; Yutaka Saito; Carol A Burke; Amit Bhatt Journal: Surg Endosc Date: 2020-05-29 Impact factor: 4.584
Authors: Robert J Schenck; Darius A Jahann; James T Patrie; Edward B Stelow; Dawn G Cox; Dushant S Uppal; Bryan G Sauer; Vanessa M Shami; Daniel S Strand; Andrew Y Wang Journal: Surg Endosc Date: 2017-03-24 Impact factor: 4.584
Authors: Tim Dg Belderbos; Hendrikus Jm Pullens; Max Leenders; Marguerite Ei Schipper; Peter D Siersema; Martijn Gh van Oijen Journal: United European Gastroenterol J Date: 2016-08-05 Impact factor: 4.623
Authors: Michael J Bartel; Ruchir Puri; Bhaumik Brahmbhatt; Wei-Chung Chen; Daniel Kim; Carlos Roberto Simons-Linares; John A Stauffer; Mauricia A Buchanan; Steven P Bowers; Timothy A Woodward; Michael B Wallace; Massimo Raimondo; Horacio J Asbun Journal: Surg Endosc Date: 2018-02-01 Impact factor: 4.584